SOUTH SAN FRANCISCO, Calif., May 29, 2025 (GLOBE NEWSWIRE) -- Alumis Inc. (ALMS), a late-stage biopharma company developing next-generation targeted therapies for patients with immune-mediated ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results